Notwithstanding this limitation, the results presented in this study clearly demonstrate that it is possible to resort to molecular pharmaceutics for the local delivery of an AhR agonist, to improve the efficacy/safety profile in the complex and multi-organ disease CF, thus counteracting infections and ameliorating the chronic inflammatory environment without causing deleterious side effects. Here, AHR is linked to glycogen storage disease VI.